Using opaganib to prevent gastrointestinal damage from radiation exposure
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome
['FUNDING_SBIR_2'] · APOGEE BIOTECHNOLOGY CORPORATION · NIH-10890883
This study is looking at a new drug called opaganib to see if it can help protect people from stomach and gut problems caused by radiation exposure, especially in emergencies like accidents or attacks, so that those affected can recover better.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | APOGEE BIOTECHNOLOGY CORPORATION (nih funded) |
| Locations | 1 site (HUMMELSTOWN, UNITED STATES) |
| Trial ID | NIH-10890883 on ClinicalTrials.gov |
What this research studies
This research investigates the use of opaganib, a novel drug, as a medical countermeasure to protect against gastrointestinal acute radiation syndrome (GI-ARS) caused by exposure to ionizing radiation. The study focuses on how opaganib can mitigate tissue damage and inflammation that occurs after radiation exposure, which is particularly relevant in scenarios of accidental or terrorist-related radiation events. The approach involves targeting specific molecular pathways that regulate cell survival and inflammatory responses, with the aim of developing an effective treatment for those affected by radiation. Patients who have been exposed to radiation may benefit from this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to ionizing radiation, particularly in the context of accidents or terrorist events.
Not a fit: Patients who have not been exposed to radiation or who have other unrelated medical conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option to prevent severe gastrointestinal damage in patients exposed to radiation.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting inflammatory pathways in radiation exposure, but the specific use of opaganib is novel.
Where this research is happening
HUMMELSTOWN, UNITED STATES
- APOGEE BIOTECHNOLOGY CORPORATION — HUMMELSTOWN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SMITH, CHARLES D — APOGEE BIOTECHNOLOGY CORPORATION
- Study coordinator: SMITH, CHARLES D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome